In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Experimental collaboration model to drive Merck cancer research

This article was originally published in Scrip

Executive Summary

In May 2010, Merck & Co launched an oncology collaborative trials network (Onconet) with leading international cancer research centres to speed up the development of its drug and vaccine candidates. The global research sites will lead the design and conduct of Phase 0 to Phase IIa clinical studies of Merck's investigational oncology candidates. Merck says that every year, the network will enrol approximately 1,200 patients in 30 to 40 clinical trials.

You may also be interested in...



More Than Hot Air: Dyson Wins UK Order For New CoVent Ventilator

UK engineering firm Dyson, best known for its vacuum cleaners, fans and hand driers, plans to make 10,000 specially designed ventilators under a UK government contract.

Ventilator Firms Across Europe Ramp Up Production To Meet ‘Unprecedented’ Demand

Production of ventilators is up by tens of thousands of units across Europe, but the supply chain is likely to come under strain with further expansion. 

ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device

The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.

Topics

UsernamePublicRestriction

Register

SC011296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel